



Platinum Resistance in Ovarian Cancer: Is This the End of the Line?

This industry symposium took place during the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain, 13th–17th September 2024.

Chairperson:	Ana Oaknin ¹
Speakers:	Philipp Harter, ² Kathleen Moore ³
	<ol style="list-style-type: none"> 1. Vall d'Hebron University Hospital, Barcelona, Spain 2. Evangelische Kliniken Essen-Mitte, Germany 3. Stephenson Cancer Center, University of Oklahoma, Norman, USA
Disclosure:	<p>Oaknin has received personal fees for advisory board membership from AbbVie, Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo, Debiopharm International, Deciphera Pharmaceuticals, Eisai, Exelisis, Genmab, GSK, ImmunoGen, Itheos, Merck Sharp & Dohme, Mersana Therapeutics, Myriad Genetics, Novocure, OncoXerna Therapeutics, PharmaMar, Regeneron, Roche, Sattuck-labs, Seagen/Pfizer, Sutro Biopharma, TORL Therapeutics, Zentalis, and Zymeworks; and personal fees for travel/accommodation from AstraZeneca, PharmaMar, and Roche. Harter has been on the advisory board for AstraZeneca, BioNTech, Clovis, Corcept, Eisai, GSK, ImmunoGen, Merck Sharp & Dohme, Miltenyi, Novartis, and Roche; and has received honoraria from AbbVie, Amgen, AstraZeneca, Clovis, Daiichi Sankyo, Eisai, Exscientia, GSK, ImmunoGen, Karyopharm, Merck Sharp & Dohme, Mersana, Miltenyi, Roche, Sotio, Stryker, and Zai Lab; and research funding to the institute from AstraZeneca, Clovis, DFG, DKH, European Union, Genmab, GSK, ImmunoGen, Novartis, Roche, and Seagen. Moore has received fees for research, educational, or advisory activities from AbbVie, Aravive, AstraZeneca, Blueprint Medicines, Eisai/Serono, Elevar Therapeutics, Eli Lilly, Genentech/Roche, GSK/Tesaro, I-Mab Biopharma, ImmunoGen, InxMed, Jiangsu Hengrui Pharmaceuticals, Merck Sharp & Dohme, Mereo BioPharma, Mersana Therapeutics, Myriad Genetics, Novartis, Tarveda Therapeutics, Vavotar Life Sciences, and VBL Therapeutics.</p>
Acknowledgements:	Medical writing assistance was provided by Brigitte Scott, MarYas Editorial Services, Cowlinge, UK.
Disclaimer:	The information/views presented are Authors' own and not necessarily those of AbbVie Inc.
Keywords:	Antibody–drug conjugate (ADC), folate receptor alpha (FR α), ovarian cancer, payload, platinum resistance, platinum-resistant ovarian cancer (PROC), recurrent ovarian cancer, relapsed ovarian cancer, tumour-associated antigen, tumour-specific antigen.
Citation:	EMJ Oncol. 2024;12[1]:69-79. https://doi.org/10.33590/emjoncol/SEKY2198 .
Support:	The symposium and publication of this article was funded by AbbVie Inc.



Meeting Summary



Approximately 80% of females with ovarian cancer are diagnosed with advanced disease, and around 70% of these females relapse within 3 years of first-line treatment. Five-year survival for newly diagnosed advanced ovarian cancer is less than 50%. Platinum-based chemotherapy is the cornerstone of systemic treatment; however, it is not appropriate for patients with relapsed ovarian cancer who had disease progression during previous platinum treatment, early symptomatic progression post-platinum treatment, or who are platinum intolerant. New drugs are needed to address the unmet need in patients with relapsed ovarian cancer who are not eligible for platinum-based chemotherapy. This article presents highlights from a satellite symposium conducted as part of the European Society for Medical Oncology (ESMO) Congress 2024, which took place from 13th–17th September 2024 in Barcelona, Spain. The objectives of the symposium were to improve understanding of the current treatment pathways and unmet needs for patients with ovarian cancer who are ineligible for platinum-based therapies, to raise awareness of the rationale for targeting folate receptor α (FR α) in a variety of novel therapeutics for platinum-resistant ovarian cancer (PROC), and to review the efficacy outcomes and side effects from recent clinical trials involving antibody–drug conjugates (ADC) in PROC. In this symposium, Ana Oaknin, Vall d’Hebron University Hospital, Barcelona, Spain, described the current landscape in advanced ovarian cancer and the unmet need in relapsed disease; Philipp Harter, Evangelische Kliniken Essen-Mitte, Germany, explored FR α -targeted therapeutics in PROC; and Kathleen Moore, Stephenson Cancer Center, University of Oklahoma, Norman, USA, discussed ADC development beyond FR α in PROC. The symposium concluded with a lively discussion, including questions from the audience, key examples of which are included in this article.

The Unmet Need in Relapsed Ovarian Cancer: What Do We Need To Do Now?

Ana Oaknin

Approximately 80% of females with ovarian cancer are diagnosed with advanced disease (International Federation of Gynecology and Obstetrics [FIGO] Stage III or IV),¹ and around 70% of these females relapse within 3 years of first-line treatment.^{2,3} Five-year survival for newly diagnosed advanced ovarian cancer is less than 50%.^{1,4} According to Oaknin: “Relapsed advanced ovarian cancer is typically incurable.” There is a significant need for better first-line treatment to improve outcomes for females with ovarian cancer.^{2,4,5-7}

First-line treatment options in newly diagnosed ovarian cancer have expanded in recent years, especially with the

introduction of poly ADP ribose polymerase (PARP) inhibitors as maintenance treatment. There was a paradigm shift in 2018, with the publication of the SOLO1 clinical trial with olaparib.⁸ This was followed by PAOLA-1 with olaparib plus bevacizumab,⁹ PRIMA with niraparib,¹⁰ and ATHENA with rucaparib.¹¹ All four trials showed a substantial progression-free survival (PFS) benefit with PARP inhibitor as maintenance therapy;⁸⁻¹² however, whether this benefit translated to overall survival (OS) benefit was not clear.^{13,14} A clinically meaningful, but not statistically significant, OS benefit compared with placebo was seen with olaparib at 7 years in SOLO1,¹³ and with olaparib plus bevacizumab in the patients with homologous recombination deficiency, but not in the intention-to-treat population as a whole, in PAOLA-1.¹⁴ The OS results from PRIMA¹⁰ were anticipated during ESMO Congress 2024.

Systemic therapy for recurrent ovarian cancer is based on platinum-containing or non-platinum-containing regimens.² There are currently no molecular biomarkers to predict the efficacy of platinum re-challenge in patients with recurrent ovarian cancer.² According to ESMO Guidelines, platinum-based therapy is not appropriate for patients with relapsed ovarian cancer who had disease progression during previous platinum treatment, early symptomatic progression post-platinum treatment, or who are platinum intolerant (Figure 1).² These patients are recommended to receive early palliative care, trabectedin-pegylated liposomal doxorubicin (PLD; i.e., in patients with platinum intolerance who have relapsed >6 months from previous platinum, the combination of trabectedin and PLD may be recommended), or single-agent (non-platinum) treatment with conditional addition of bevacizumab (i.e., in patients

without contraindications to bevacizumab and in those not previously exposed to bevacizumab),² based on the results of the AURELIA trial.¹⁵ However, the addition of bevacizumab to chemotherapy did not improve OS (HR=0.85; 95% CI: 0.66 - 1.08; $p < 0.174$).¹⁵

In AURELIA, patients with platinum resistance received investigator's choice chemotherapy (ICC; weekly paclitaxel, PLD, or topotecan) with or without bevacizumab.¹⁵ Addition of bevacizumab to ICC was associated with a clinically meaningful and statistically significant improvement in PFS (hazard ratio [HR]: 0.48; 95% CI: 0.38–0.60; $p < 0.001$).¹⁵

In an exploratory analysis according to chemotherapy cohort in AURELIA, weekly paclitaxel emerged as a single-agent chemotherapy choice of interest, with

Figure 1: ESMO guidelines for patients with recurrent ovarian cancer who are ineligible for platinum-based therapy.²




Figure adapted from González-Martín A et al.²

EOC: epithelial ovarian cancer; ESMO: European Society for Medical Oncology; MCBS: ESMO-Magnitude of Clinical Benefit Scale; PLD: pegylated liposomal doxorubicin; TF1p: treatment-free interval from last platinum.

* Patient choice and quality-of-life issues may also suggest that platinum is not the best option.

† In patients with platinum intolerance who have relapsed >6 months from previous platinum, the combination of trabectedin and PLD may be recommended [II, C; ESMO-MCBS v1.1 score: 2 for patients with platinum-sensitive disease; EMA approved, not FDA approved].

‡ Weekly paclitaxel, PLD, topotecan, or gemcitabine.

§ ESMO-MCBS v1.1104 was used to calculate scores for new therapies/indications approved by the EMA or FDA.

an objective response rate (ORR) of 28.8% versus 7.9% for PLD and 3.3% for topotecan.^{16,17}

Phase III studies with novel therapies added to weekly paclitaxel compared to weekly paclitaxel alone have not shown a benefit in patients with platinum resistance.¹⁸⁻²⁰ This includes the AGO OVAR 2.29 trial, in which the addition of atezolizumab, a humanised programmed death-ligand 1 (PD-L1) antibody, to single-agent, non-platinum-based chemotherapy (weekly paclitaxel or PLD) plus bevacizumab did not significantly improve PFS or OS.²¹

ADCs comprise an antibody with high affinity for tumour-associated antigens (the target for ADCs); a drug payload, which is a potent chemotherapy that induces tumour cell death when it is internalised

and released; and a linker that controls the release of the payload at the target site.²² According to Oaknin, ideally, the tumour-associated antigens should have a high level of expression on malignant cells, and no or negligible expression on non-malignant tissue. Moreover, the target tumour-associated antigens should be present on the cell surface, thus accessible to the ADC, and should be internalised, by which process the ADC is transported into the cell.

There are several ADCs in clinical development in ovarian cancer (Table 1). Mirvetuximab soravtansine (MIRV),²³ targeting FR α , and trastuzumab deruxtecan (T-DXd),²⁴ targeting human epidermal growth factor receptor 2 (HER2), are the only ADCs that have been approved by the U.S. FDA. There are no ADCs approved in Europe.

Table 1: Antibody–drug conjugates of clinical interest in ovarian cancer.

Antibody–Drug Conjugate	Target	Linker	Payload
Tisotumab vedotin ²⁵⁻²⁷	Tissue factor	Cleavable	MMAE
Mirvetuximab soravtansine (MIRV) ²⁸⁻³¹	FR α	Cleavable	DM4
Luveltamab tazevibulin (STRO-002) ³²⁻³⁴	FR α	Cleavable	DAR4
Farletuzumab ecteribulin (MORAb-202) ³⁵⁻³⁷	FR α	Cleavable	Eribulin
Trastuzumab deruxtecan (T-DXd) ³⁸⁻⁴¹	HER2	Cleavable	Topoisomerase I inhibitor
Trastuzumab duocarmazine (SYD985) ⁴²⁻⁴⁴	HER2	Cleavable	Duocarmycin
Trastuzumab emtansine (T-DM1) ⁴⁵⁻⁴⁸	HER2	Non-cleavable	DM1
BB-1701 ^{49,50}	HER2	Cleavable	Eribulin
DB-1303 (BNT323) ^{51,52}	HER2	Cleavable	Topoisomerase I inhibitor
Sacituzumab govitecan (SG) ⁵³⁻⁵⁵	Trop-2	Cleavable	SN38
Sacituzumab tirumotecan (Sac-TMT; SKB264; MK-2870) ⁵⁶⁻⁵⁸	Trop-2	Cleavable	KL610023
Raludotatug deruxtecan (R-DXd; DS-6000a) ^{59,60}	CDH6	Cleavable	Topoisomerase I inhibitor
SGN-B7H4V ^{61,62}	B7-H4	Cleavable	MMAE
SGN-ALPV ^{63,64}	ALPP; ALPPL2	Cleavable	MMAE

Table compiled by Oaknin.

MMAE: monomethyl auristatin E.

Oaknin concluded: “We need to develop new drugs to address the unmet need in relapsed ovarian cancer. Antibody–drug conjugates represent another paradigm shift in the treatment of this cancer. ADCs enable us to deliver highly potent chemotherapy into tumour cells through targeting tumour-associated antigens.”

Exploring Folate Receptor- α -Targeted Therapeutics in Platinum-Resistant Ovarian Cancer

Philipp Harter

FR α is an attractive candidate for molecularly targeted approaches for ovarian cancer as it has almost ubiquitous expression on the surface of ovarian cancer cells, and can internalise large molecules containing a cytotoxic payload.⁶⁵

Expression of FR α is characterised using immunohistochemistry (IHC) and classified into low, medium, and high based on the percentage of cells with staining and the intensity of staining. A study of FR α expression in pooled samples from patients with high-grade serous ovarian cancer showed that around two-thirds of samples had positive staining intensity ≥ 2 (PS2+) in $\geq 50\%$ of cells, and around one-third had PS2+ in $\geq 75\%$ of cells.⁶⁶

MIRV is a first-in-class ADC comprising an FR α -binding antibody, a cleavable linker, and a maytansinoid DM4 payload (a potent tubulin-targeting agent).^{28,29} In the confirmatory Phase III MIRASOL trial, patients with PROC, high-grade serous histology, and FR α detected by IHC with PS2+ in $\geq 75\%$ of viable tumour cells were randomised to MIRV or ICC (paclitaxel, PLD, or topotecan).³¹ Patients included in the trial were heavily pretreated, with approximately half the patients having received three prior lines of systemic therapy.³¹

PFS, the primary endpoint, was statistically significantly longer with MIRV versus ICC: median PFS was 5.62 months (95% CI: 4.34–5.95) with MIRV and 3.98

months (95% CI: 2.86–4.47) with ICC ($p < 0.001$).³¹ In terms of key secondary endpoints, ORR was 42.3% with MIRV and 15.9% with ICC (ORR difference: 26.4%; 95% CI: 18.4–34.4), and OS results were statistically significant, with an HR of 0.67 (95% CI: 0.50–0.89; $p = 0.0046$) (Figure 2).³¹

Harter emphasised that this was the first Phase III trial to show positive OS in PROC comparing a new drug versus ICC. Furthermore, no new safety signals were identified compared with ICC,³¹ and the discontinuation rate due to adverse events in the MIRV arm was 9% versus 16% with ICC.³¹

Ocular events, such as blurred vision, keratopathy, and dry eye, were more common with MIRV than with ICC.³¹

Harter stated that the ocular side effects are manageable, but clinicians will need to learn about and gain experience with these effects.

Several other drugs targeting FR α are in clinical development.⁶⁷ For example, luveltamab tazevibulin was shown to be efficacious in a Phase I trial including patients with PROC (any level of FR α expression), with an overall response rate of 31.7% and a disease control rate of 78%.³³ The most common treatment-emergent adverse events of any grade in the trial were neutropenia, nausea, fatigue, and arthralgia.³³ Neuropathy was also noted as an important side effect in the trial.³³ A Phase II/III trial with luveltamab tazevibulin is ongoing.⁶⁸

Farletuzumab ecteribulin was evaluated in a Phase I trial including patients with high-grade serous ovarian cancer or other histologies.³⁶ ORR was 25.0% and 52.4% for 0.9 mg/kg and 1.2 mg/kg farletuzumab ecteribulin, respectively.³⁶ However, a limiting toxicity, interstitial lung disease/pneumonitis, was observed in this trial, occurring in 37.5% and 66.7% of patients receiving 0.9 mg/kg and 1.2 mg/kg, respectively.³⁶

Another drug targeting FR α , rinatabart sesutecan, is currently being evaluated in a Phase I/II dose escalation and expansion trial,⁶⁹ with initial data due at the ESMO Congress 2024.

Figure 2: Overall survival in the confirmatory Phase III MIRASOL trial in patients with platinum-resistant ovarian cancer.³¹




Figure adapted from Moore et al.³¹ Data cut-off: 6 March 2023. Median follow-up time: 13.11 months.

*Intent-to-treat population.

HR: hazard ratio; IC: investigator's choice; MIRV: mirvetuximab soravtansine; mOS: median overall survival.

There are already attempts to combine ADCs with other agents. For example, in the FORWARD II trial, a combination of MIRV and bevacizumab in patients with relapsed FR α -expressing ovarian cancer showed “very impressive response rates”, and was well tolerated, with adverse events as expected based on the side effect profiles of each drug, and there were no new safety signals.⁷⁰

Harter concluded that MIRV has shown PFS benefit in PROC in the MIRASOL trial, and there are multiple further trials with drugs targeting FR α ongoing or under development. Areas of interest for future research include efficacy in a broader patient population regarding FR α status and effectiveness of ADCs in earlier lines of therapy.

Exploring Antibody–Drug Conjugate Development Beyond Folate Receptor- α in Platinum-Resistant Ovarian Cancer

Kathleen Moore

Moore summarised that there are numerous ADCs currently in development (including approximately 190 for solid tumours), with a variety of tumour-associated antigens and proprietary linkers, and a range of cytotoxics (mainly in two categories: microtubule inhibitors and camptothecins). ADCs differ chemically in terms of the drug-to-antibody ratio, the linkers, and the payloads; however, whether this makes a difference clinically is unknown.

According to Moore, the tumour-associated antigens aside from FR α that are of particular interest in gynaecological cancers include B7H4, claudin 6, cadherin-6 (CDH6), HER2, trophoblast antigen 2 (Trop-2), and mesothelin (MSLN).

B7H4 is a transmembrane protein widely expressed across many solid tumours.⁷¹ B7H4 expression has been reported in approximately 75% of patients with advanced epithelial ovarian cancer, and approximately 50% of patients had >50% of cells with any B7H4 staining intensity.⁷¹ However, in Moore's opinion, the association of B7H4 with ovarian cancer prognosis has not been validated, there are no biomarkers for B7H4, and little is known about targeting B7H4.

A total of 75 patients with ovarian cancer were treated with SGN-B7H4V in a Phase I trial, and the overall response rate across all dose levels was 20%.⁶² Moore considered this a "modest signal" in these heavily pre-treated patients that merited further investigation. Other ADCs targeting B7H4 in clinical research include puxitaug samrotecán (AZD8205)⁷¹ and XMT-1660.⁷²

Claudin 6, another transmembrane protein, is highly overexpressed in many solid tumours, including ovarian cancer, and has little to no expression in non-malignant tissues.⁷³ Hence, Moore noted that claudin 6 may be the closest to a lineage marker (i.e., a 'tumour-specific' rather than a 'tumour-associated' antigen) among the solid tumour targets.

Initial results from a first-in-human study of TORL-1-23, an ADC targeting claudin 6, in epithelial ovarian cancer showed an ORR of 32%.⁷³ Moore considered claudin 6 to be a "different and exciting target for gynaecological cancers".

CDH6 is a transmembrane protein that is highly overexpressed in epithelial ovarian cancer.⁷⁴ Moore noted that the function of CDH6 in ovarian cancer and the impact on prognosis has not yet been fully elucidated. Raludotatug deruxtecán (R-DXd), an ADC targeting CDH6, has been tested in a Phase I trial in patients with PROC, irrespective of biomarkers.⁷⁵ The confirmed overall response rate was 48.6% (95% CI: 31.9–65.6) in the 4.8–6.4 mg/kg ovarian cancer cohort, duration of response was 11.2 months (95% CI: 3.1–not estimable [NE]), and median PFS was 8.1 months (95% CI: 5.3–NE).⁷⁵

Moore described these results as "a very strong signal right out of the gates"; however, this is not sufficient to progress into Phase III trials versus standard-of-care treatments because dose optimisation and therapeutic windows for ADCs need to be understood. Therefore, the REJOICE-Ovarian01 randomised Phase II/III trial is being conducted to identify the optimal dose of R-DXd (4.8, 5.6, or 6.4 mg/kg) for efficacy and safety to inform the Phase III trial.⁷⁶

CUSP06/AMT-707 is another ADC targeting CDH6 of interest for the treatment of ovarian cancer, and clinical data are awaited.^{77,78}

HER2 has long been known to be a target in ovarian cancer; however, this target has received little ovarian cancer research attention until recently.⁷⁹ HER2+ IHC 3+ is uncommon in high-grade serous ovarian cancer (2–5%),^{80–82} whereas HER2+ IHC 2+ occurs more frequently (8–18%).^{80,82,83} The incidence of HER2+ IHC 1+ is not yet known.

ORR in patients with PROC receiving T-DXd, which targets HER2, in the DESTINY-PanTumor02 trial was 45% (18/40) for all patients, 63.6% (7/11) for IHC 3+, and 36.8% (7/19) for IHC 2+;⁸⁰ however, these results need to be confirmed in a larger dataset.

The frequency of strongly positive cases of Trop-2 with immuno-staining is >40% of serous, approximately 40% of endometrioid, approximately 30% of mucinous, and approximately 20% of clear cell ovarian cancers, as well as >20% of carcinosarcomas of the ovary.⁸⁴ There is growing interest in ADCs targeting Trop-2 in ovarian cancer.

Finally, MSLN is highly overexpressed in many solid tumours, and has recently re-emerged as a target of interest in ovarian cancer following a confirmed ORR of 41.9% (95% CI: 24.5–60.9) with RC88, an ADC with a monomethyl auristatin E payload, in a platinum-resistant population.⁸⁵

Moore concluded that ADCs are some of the most promising new agents in gynaecological cancers, and the variety of ADCs in development for ovarian cancer is exciting; however, better understanding of sequencing of ADCs, payload factors, and potential resistance mechanisms is needed.

Digesting the Data: Reflections on Antibody–Drug Conjugates

Panel discussion with all speakers

Four Key Questions from the Audience During the Panel Discussion are Covered Below

The experts discussed the potential use of technology, such as analysis of circulating tumour cells or circulating tumour DNA (ctDNA), to alleviate the delay in obtaining tissue biopsies in clinical trials. Moore considered that ctDNA technology in ovarian cancer is not sufficiently mature or reliable to warrant replacing tumour biopsies and biomarkers with a circulating marker. As technologies improve, this approach may be helpful as part of optimising treatment for patients.

The approach for the patient newly diagnosed with PROC was considered, including whether clinicians should start testing for FR α early in the patient journey. Harter noted that FR α testing does not necessarily have to be conducted early, unless it is important for the patient's therapy; however, clinicians should be aware of the location of the

patient's tissue specimens, with these specimens ideally kept in the centre where the patient is being treated, to allow timely testing, if and when required.

A further topic in the panel discussion was the management of ocular toxicity under MIRV therapy. Oaknin emphasised that clinicians should be aware of the type of eye events the patient might develop with this treatment, ensure that they follow their patients carefully from the beginning of therapy, and identify ocular events as early as possible. In addition, clinicians should regularly ask patients if they are suffering from any kind of ocular symptoms and refer patients to an ophthalmologist as necessary. Moore emphasised that patients should be encouraged to inform their doctor even if they are having only mild ocular symptoms so that mitigation strategies can be implemented. In addition, Moore stated that it is important that clinicians acknowledge the patient's ocular symptoms and treat them early.

Whether treatments have an impact on the biology of the cancer cell, and the possibility of restoring platinum sensitivity with MIRV, was also considered by the panel. Moore outlined that research is required in this area, including assessing the efficacy of paclitaxel before and after MIRV, responses with subsequent lines of therapy, and treatment sequencing. Moore added that MIRV and weekly paclitaxel are two of the most active agents in the platinum-resistant space, so these are the treatments of choice (in the USA) if the patient has not yet received these drugs and has no contraindications.

References

1. Torre LA et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(4):284-96.
2. González-Martín A et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol.* 2023;34(10):833-48.
3. Ledermann JA et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013;24(Suppl 6):vi24-32.
4. du Bois A et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). *Cancer.* 2009;115(6):1234-44.
5. Tewari KS et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. *J Clin Oncol.* 2019;37(26):2317-28.
6. Bookman MA et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. *J Clin Oncol.* 2009;27(9):1419-25.
7. Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med.* 2011;365:2473-83.

8. Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*. 2018;379(26):2495-505.
9. Ray-Coquard I et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med*. 2019;381(25):2416-28.
10. González-Martín A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*. 2019;381(25):2391-402.
11. Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). *J Clin Oncol*. 2022;40(34):3952-64.
12. González-Martín A et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. *Eur J Cancer*. 2023;189:112908.
13. DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. *J Clin Oncol*. 2023;41(3):609-17.
14. Ray-Coquard I et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. *Ann Oncol*. 2023;34(8):681-92.
15. Pujade-Lauraine E et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. *J Clin Oncol*. 2014;32(13):1302-8.
16. Poveda AM et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized Phase III AURELIA trial. *J Clin Oncol*. 2015;33(32):3836-8.
17. Poveda AM et al. Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIg AURELIA randomised phase III trial. *Ann Oncol*. 2012;23(Suppl 17):LBA26.
18. Arend RC et al. Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). *J Clin Oncol*. 2023;41(Suppl 16):5505.
19. Fuh KC et al. AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. *J Clin Oncol*. 2024;42(Suppl 17):LBA5515.
20. Vergote IB et al. Tumor treating fields (TTFields) therapy in platinum-resistant ovarian cancer: results from the ENGOT-ov50/GOG-3029/INNOVATE-3 phase 3 study. Abstract 1350. European Society of Gynaecological Oncology (ESGO) Congress, 7-10 March, 2024.
21. Marmé F et al. Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study. *J Clin Oncol*. 2024;42(Suppl 17):LBA5501.
22. Marks S, Naidoo J. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach. *Lung Cancer*. 2022;163:59-68.
23. U.S. Food and Drug Administration (FDA). FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. 2022. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant>. Last accessed: 25 September 2024.
24. U.S. Food and Drug Administration (FDA). FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. 2024. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2>. Last accessed: 25 September 2024.
25. Vergote I et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. *N Engl J Med*. 2024;391(1):44-55.
26. Seagen Inc. A study of weekly tisotumab vedotin for patients with platinum-resistant ovarian cancer with safety run-in (innovaTV 208). NCT03657043. <https://clinicaltrials.gov/study/NCT03657043>.
27. Mahdi H et al. Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208). *J Clin Oncol* 2019;37(Suppl 15):TPS5602.
28. Ab O et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. *Mol Cancer Ther*. 2015;14(7):1605-13.
29. Moore KN et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. *J Clin Oncol*. 2017;35(10):1112-8.
30. Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. *J Clin Oncol*. 2023;41(13):2436-45.
31. Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. *N Engl J Med*. 2023;389(23):2162-74.
32. Li X et al. Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers. *Mol Cancer Ther*. 2023;22(2):155-67.
33. Oaknin A et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. Abstract 5508. American Society of Clinical Oncology (ASCO) Annual Meeting, 2-6 June, 2023.
34. Sutro Biopharma, Inc. Study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate in ovarian and endometrial cancers. NCT03748186. <https://www.clinicaltrials.gov/study/NCT03748186>.
35. Shimizu T et al. First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-α-positive advanced solid tumors. *Clin Cancer Res*. 2021;27(14):3905-15.
36. Nishio S et al. Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): results from the expansion part of a phase 1 trial. *J Clin Oncol*. 2022;40(Suppl 16):5513.
37. Eisai Inc. A study of MORAb-202 (herein referred to as farletuzumab ecteribulin) in participants with solid tumors. NCT03386942. <https://clinicaltrials.gov/study/NCT03386942>.
38. Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the

- DESTINY-PanTumor02 phase II trial. *J Clin Oncol.* 2024;42(1):47-58.
39. National Cancer Institute (NCI). Testing the combination of DS-8201a and olaparib in HER2-expressing cancers with expansion in patients with endometrial cancer. NCT04585958. <https://clinicaltrials.gov/study/NCT04585958>.
 40. AstraZeneca. A phase 2 study of T-DXd in patients with selected HER2-expressing tumors (DPT02). NCT04482309. <https://www.clinicaltrials.gov/study/NCT04482309>.
 41. AstraZeneca. A study of T-DXd for the treatment of solid tumors harboring HER2-activating mutations (DPT01). NCT04639219. <https://clinicaltrials.gov/study/NCT04639219>.
 42. Yao HP et al. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress. *Drug Discov Today.* 2021;26(8):1857-74.
 43. Byondis BV. SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma. NCT04205630. <https://clinicaltrials.gov/study/NCT04205630>.
 44. Byondis BV. Phase I study of SYD985 with niraparib in patients with solid tumors. NCT04235101. <https://clinicaltrials.gov/study/NCT04235101>.
 45. Nicoletti R et al. T-DM1, a novel antibody–drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. *Clin Exp Metastasis.* 2015;32(1):29-38.
 46. Hoffmann-La Roche. A study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors (BOUQUET). NCT04931342. <https://clinicaltrials.gov/study/NCT04931342>.
 47. National Cancer Institute (NCI). Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (the MATCH screening trial). NCT02465060. <https://clinicaltrials.gov/study/NCT02465060>.
 48. Rinnerthaler G et al. HER2 directed antibody–drug-conjugates beyond T-DM1 in breast cancer. *Int J Mol Sci.* 2019;20(5):1115.
 49. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. A first-in-human study of multiple doses of BB-1701 in subjects with locally advanced/metastatic HER2-expressing solid tumors. NCT04257110. <https://clinicaltrials.gov/study/NCT04257110>.
 50. Ma F et al. A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. *J Clin Oncol.* 2023;41(Suppl 16):3029.
 51. DualityBio Inc. A phase 1/2a study of DB-1303/BNT323 in advanced/metastatic solid tumors. NCT05150691. <https://www.clinicaltrials.gov/study/NCT05150691>.
 52. Moore KN et al. Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1/2a study. *J Clin Oncol.* 2023;41(Suppl 16):3023.
 53. Bardia A et al. Sacituzumab govitecan, a Trop-2-directed antibody–drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. *Ann Oncol.* 2021;32(6):746-56.
 54. Saxena A et al. TROPiCS-03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors. *J Clin Oncol* 2020;38(Suppl 15):TPS3648.
 55. Icahn School of Medicine at Mount Sinai. Sacituzumab govitecan in combination with cisplatin in platinum sensitive recurrent ovarian and endometrial cancer. NCT06040970. <https://clinicaltrials.gov/study/NCT06040970>.
 56. Fang W et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study. *J Clin Oncol.* 2023;41(Suppl 16):9114.
 57. Merck Sharp & Dohme LLC. Sacituzumab tirumotecan (MK-2870) as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors (MK-2870-008) (TroFuse-008). NCT06049212. <https://clinicaltrials.gov/study/NCT06049212>.
 58. Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. *Annals Oncol.* 2024;35:S548.
 59. Hamilton EP et al. Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). *J Clin Oncol.* 2022;40(Suppl 16):3002.
 60. Daiichi Sankyo. A study of DS-6000a in subjects with advanced renal cell carcinoma and ovarian tumors. NCT04707248. <https://www.clinicaltrials.gov/study/NCT04707248>.
 61. Seagen Inc. A study of SGN-B7H4V in advanced solid tumors. NCT05194072. <https://clinicaltrials.gov/study/NCT05194072>.
 62. Perez C et al. First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). Abstract 660MO. European Society for Medical Oncology (ESMO) Annual Meeting, 20-24 October, 2023.
 63. Seagen Inc. A study of SGN-ALPV in advanced solid tumors. NCT05229900. <https://clinicaltrials.gov/study/NCT05229900>.
 64. Lakhani NJ et al. Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress). *J Clin Oncol.* 2022;40(Suppl 16):TPS3159.
 65. Chelariu-Raicu A et al. Integrating antibody drug conjugates in the management of gynecologic cancers. *Int J Gynecol Cancer.* 2023;33(3):420-9.
 66. Deutschman E et al. Folate receptor alpha prevalence and association with ovarian cancer patient and disease characteristics 36th European Congress of Pathology (ECP) 2024. PS-10-012. Available at: <https://online.flippingbook.com/view/677164284/98/>. Last accessed: 25 September 2024.
 67. Udofa E et al. Antibody drug conjugates in the clinic. *Bioeng Transl Med.* 2024;DOI: 10.1002/btm2.10677.
 68. Oaknin A et al. Efficacy and safety of luveltamab tazevibulin vs investigator's choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FR α): the REFRA α ME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study. Abstract TPS5637. ASCO Annual Meeting. 31 May-4 June, 2024.
 69. Call J et al. Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody–drug conjugate, in patients with locally advanced and/or metastatic solid tumors. *J Clin Oncol.* 2023;41(Suppl 16):TPS3157.
 70. Gilbert L et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody–drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. *Gynecol Oncol.* 2023;170:241-7.
 71. Meric-Berstam F et al. First-in-human study of the B7-H4 antibody–drug

- conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. Abstract TPS3153. American Society of Clinical Oncology (ASCO) Annual Meeting. 3-7 June, 2022.
72. Hamilton E et al. XMT-1660: a phase 1B trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers. Abstract 1420. IGCS Annual Global Meeting, 29 September-1 October, 2022.
 73. Konecny GE et al. Initial results of dose finding in a first-in-human phase 1 study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors. Abstract 3082. ASCO Annual Meeting, 2-6 June, 2023.
 74. Suzuki H et al. Raludotatug deruxtecan, a CDH6-targeting antibody–drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models. *Mol Cancer Ther.* 2024;23(3):257-71.
 75. Moore KN et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase I study. Abstract 745 MO. ESMO Annual Meeting, 20-24 October, 2023.
 76. Daiichi Sankyo. A study of raludotatug deruxtecan (R-DXd) in subjects with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. NCT06161025. <https://clinicaltrials.gov/study/NCT06161025>.
 77. Lu W et al. CUSP06/AMT-707, a new CDH6-targeting antibody–drug conjugate, demonstrates potent antitumor activity in preclinical models. *Cancer Res.* 2023;83(Suppl 7):6320.
 78. Spira AI et al. A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6)-directed antibody–drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. *J Clin Oncol.* 2024;42(Suppl 16):TPS3166.
 79. Shepard HM. Trastuzumab: dreams, desperation and hope. *Nat Rev Cancer.* 2024;24(5):287-8.
 80. Makker V et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study. Abstract 460150. SGO Annual Meeting on Women's Cancer, 16-18 March, 2024.
 81. Yan M et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. *Cancer Metastasis Rev.* 2015;34(1):157-64.
 82. Tuefferd M et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. *PLoS One.* 2007;2(11):e1138.
 83. Ersoy E et al. HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas. *Int J Gynecol Pathol.* 2022;41(4):313-9.
 84. Dum D et al. Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: a tissue microarray study on 14,766 tumors. Abstract 83P. ESMO Annual Meeting, 9-13 September, 2022.
 85. Liu Y et al. The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: results from a first-in-human phase 1/2 study. Abstract 5551. ASCO Annual Meeting, 31 May- 4 June, 2024.

FOR REPRINT QUERIES PLEASE CONTACT: INFO@EMJREVIEWS.COM